CTX310 cuts triglycerides 55% in humans
- CRISPR Therapeutics’ one-shot gene-editing drug CTX310 has now shown real human lipid-lowering, pushing in-vivo CRISPR beyond rare disease into heart risk. - In the highest-dose group, triglycerides fell 55% on average and LDL fell 49%, after a single IV infusion editing ANGPTL3 in the liver. - That matters because chronic cardiometabolic disease is a far bigger market — and a much tougher safety, pricing, and durability test.
Gene editing just took a step into a very different kind of disease. Not a rare inherited disorder with a tiny patient pool, but high blood lipids — the giant, messy world of cardiovascular risk. That is why CTX310 matters. CRISPR Therapeutics is showing that a one-time in-vivo edit can push down triglycerides and LDL in actual human patients, not just in animals or lab models. (crisprtx.com) ### What is CTX310 actually doing? CTX310 is an in-vivo CRISPR/Cas9 therapy aimed at ANGPTL3, a liver-made protein that helps regulate blood fats. The drug is delivered by lipid nanoparticles through an IV infusion, gets into liver cells, and edits the ANGPTL3 gene so the body makes less of that protein. The basic idea is simple — if you permanently turn down ANGPTL3, you may get a durable drop in triglycerides and LDL without chronic dosing. (crisprtx.com) ### Why target ANGPTL3? ANGPTL3 is one of the cleaner lipid targets in biology. People born with naturally low ANGPTL3 tend to have lower triglycerides and LDL, which makes the gene attractive as a therapeutic switch. Drug companies have already validated the target with antibody approaches, but those still require repeat treatment. CTX310 is trying the harder version of the trick — edit once, then let the effect persist. (newsroom.heart.org) ### What did the human data show? The headline numbers came from the highest-dose cohort in the ongoing Phase 1 study. A single treatment produced a mean 73% reduction in circulating ANGPTL3, a mean 55% drop in triglycerides, and a mean 49% drop in LDL from baseline, with maximum reductions reaching 8(newsroom.heart.org)e data presented publicly. (crisprtx.com) ### How early is this? Still early. The dataset was first disclosed as top-line Phase 1 data in May 2025, then expanded in June 2025, and later presented in fuller form in November 2025 at the American Heart Association meeting, with simultaneous publication tied to that presentation. So the science is more real than a teaser slide, but this is not a registrational trial and not close to an approval decision. (crisprtx.com) ### What about safety? So far, the company has described the profile as well tolerated in the early trial. That is encouraging, but this is exactly where everyone will stay cautious. In-vivo editing for cardiovascular disease sets a much higher bar than ultra-severe rare disease because the patients can live for years on existing medicines. A one-time permanent edit has to look not just effective, but boringly safe. (crisprtx.com) ### Why is this a bigger deal than one biotech update? Because cardiovascular disease is where gene editing stops being a niche platform story and starts colliding with mainstream medicine. If a single infusion can replace ye(crisprtx.com) and who should get a permanent therapy for a chronic condition. (crisprtx.com) ### What is the catch? The catch is that early lipid reductions are not the same thing as proven clinical benefit. Lower triglycerides and LDL are promising, but doctors and payers will want to know how durable the edit is, how consistent the response is across more patients, and whether safety still looks clean after longer follow-up. Basically, the field now has a proof-of-concept signal — not the final answer. (crisprtx.com) ### Bottom line? CTX310 looks like one of the clearest signs yet that in-vivo CRISPR can move beyond rare disease and into mass-market cardiometabolic medicine. The numbers are strong enough to get attention. Now the whole story turns on whether those numbers hold up — safely, durably, and at scale. (crisprtx.com)
